Bold Moves

Deliver first-in-class science

Win the digital race in pharma

Unleash the power of our people

Working to empower an underserved patient community

While many factors can contribute to hair loss, including aging, stress or medical treatment, one of the lesser-known causes is an autoimmune disease called alopecia areata, which affects approximately 3 million people in the U.S.1

People unfamiliar with alopecia areata may think of hair loss as just cosmetic, but this chronic disease can have an unpredictable and profound impact on a person’s life, well beyond the hair loss itself.2

Because awareness remains an unmet need, social stigmatization endures. Some individuals living with alopecia areata may face periods of bullying or feel that they need to explain their condition to others.3

Lily, a Pfizer colleague who has lived with alopecia areata since childhood, recently shared some of her experiences with the condition and shed light on the challenges this patient community faces each day.

The onset is extremely jarring, seemingly without a catalyst. The extent of loss is unknown. The areas of loss will be unknown. The extent to which it will continue is unknown. Those questions, none of which have ever had an answer, have been emotionally debilitating.​​​​​​​"


Pfizer Colleague Living with Alopecia Areata

In 2021, Pfizer is committed to educating the world about this misunderstood disease while working to advance innovative potential treatments. We look forward to sharing more late-stage data for our breakthrough oral JAK3/TEC inhibitor, ritlecitinib, which, if successful in clinical trials, could represent a significant scientific innovation for patients who currently have limited and largely cosmetic options.

3 million​​​​​​​ 

Approximately 3 million people in the U.S. experience a form of hair loss due to an autoimmune disease called alopecia areata.1

Meet Lily, a Pfizer colleague living with an autoimmune disease called alopecia areata. Beyond hair loss, this condition can also have a significant impact on a person’s mental well-being.



1Benigno, M., Anastassopoulos, K. P., Mostaghimi, A., Udall, M., Daniel, S. R., Cappelleri, J. C., Chander, P., Wahl, P. M., Lapthorn, J., Kauffman, L., Chen, L., & Peeva, E. (2020). A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States. Clinical, cosmetic and investigational dermatology, 13, 259–266.

2Villasante Fricke, A. C., & Miteva, M. (2015). Epidemiology and burden of alopecia areata: a systematic review. Clinical, cosmetic and investigational dermatology, 8, 397–403.

3Christensen, T., Yang, J. S., & Castelo-Soccio, L. (2017). Bullying and Quality of Life in Pediatric Alopecia Areata. Skin appendage disorders, 3(3), 115–118.


Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories